Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: A multicenter phase 1-2 clinical trial

Blood

Volumn 97, Issue 6, 2001, Pages 1590-1597

  Haddad, Elie ^a   Paczesny, Sophie ^b   Leblond, Veronique ^b   Seigneurin, Jean Marie ^b   Stern, Marc ^b   Achkar, Antoine ^b   Bauwens, Marc ^b   Delwail, Vincent ^b   Debray, Dominique ^b   Duvoux, Christophe ^b   Hubert, Philippe ^b   Hurault De Ligny, Bruno ^b   Wijdenes, John ^b   Durandy, Anne ^b   Fischer, Alain ^b  

^a Serv de Pediat Gen   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6 ANTIBODY;

ADULT; ARTICLE; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0035869536     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.6.1590     Document Type: Article

References (67)

1. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients
2. A monoclonal immunoblastic sarcoma in donor cells bearing Epstein-Barr virus genomes following allogeneic marrow grafting for acute lymphoblastic leukemia
3. Advances in the diagnosis and treatment of EBV-associated lymphoproliferative diseases in immunocompromised hosts
4. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression
5. Clonal analysis of transplant-associated lymphoproliferations based on the structure of the genomic termini of the Epstein-Barr virus
6. Latent and replicating forms of Epstein-Barr virus DNA in lymphomas and lymphoproliferative diseases
7. B-cell lymphoproliferative disorders after bone marrow transplant: An analysis of ten cases with emphasis on Epstein-Barr virus detection by in situ hybridization
8. Epstein-Barr virus and its replication
9. Epstein-Barr virus
10. Epstein-Barr virus-associated B-cell proliferations of diverse clonal origins after bone marrow transplantation in a 12-year-old patient with severe combined immunodeficiency
11. Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders
12. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation
13. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation
14. Evidence for restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders
15. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency
16. Epstein-Barr virus-associated lymphoproliferative disorders in immunocompromised individuals
17. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study
18. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants: CAMPATH Users
19. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy
20. Increased incidence of lymphoproliferative disorders after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients
21. Preliminary experience with intestinal transplantation in infants and children
22. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children
23. Bone marrow transplantation (BMT) in Europe for primary immunodeficiencies other than severe combined immunodeficiency: A report from the European Group for BMT and the European Group for Immunodeficiency
24. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation
25. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors
26. Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir: Two cases after solid organ transplantation
27. Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy
28. Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin
29. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
30. Treatment of severe Epstein-Barr virus-induced polyclonal B-lymphocyte proliferation by anti-B-cell monoclonal antibodies: Two cases after HLA-mismatched bone marrow transplantation
31. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation
32. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome
33. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation
34. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders
35. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients
36. Interleukin-6: An overview
37. Biological and clinical aspects of interleukin 6
38. The biology of interleukin-6
39. Interleukin-6 family of cytokines and gp130
40. Interleukin-6 production in high-grade B lymphomas: Correlation with the presence of malignant immunoblasts in acquired immunodeficiency syndrome and in human immunodeficiency virus-seronegative patients
41. Interleukin-6 in biology and medicine
42. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
43. Establishment of two interleukin 6 (B cell stimulatory factor 2/interferon beta 2)-dependent human bone marrow-derived myeloma cell lines
44. Interleukin-6 in human multiple myeloma
45. Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells
46. Monocyte-derived human B-cell growth factor identified as interferon-beta 2 (BSF-2, IL-6)
47. Interleukin-6 production in posttransplant lymphoproliferative disease
48. Role of IL-6 in promoting growth of human EBV-induced B-cell tumors in severe combined immunodeficient mice
49. Growth autonomy and tumorigenicity of interleukin 6-dependent B cells transfected with interleukin 6 cDNA
50. Expression of an exogenous interleukin 6 gene in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity
51. Human recombinant dimeric IL-6 binds to its receptor as detected by anti-IL-6 monoclonal antibodies
52. Same peculiar subset of HML1+ lymphocytes present within normal intestinal epithelium is associated with tumoral epithelium of gastrointestinal carcinomas
53. Prospective study of the occurrence of monoclonal gammopathies following bone marrow transplantation in young children
54. Detection of Epstein-Barr virus in epidermal skin lesions of an immunocompromised patient
55. Amplification and characterization of herpesvirus DNA in cerebrospinal fluid from patients with acute encephalitis
56. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia
57. Dysregulated interleukin-6 expression produces a syndrome resembling Castleman's disease in mice
58. Interleukin-6 and the acute phase response
59. Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: Effect on lymphoma growth and on B clinical symptoms
60. Brief report: Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody
61. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody
62. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders
63. Epstein-Barr virus latent membrane protein-1 oncogene deletions: Correlations with malignancy in Epstein-Barr virus-associated lymphoproliferative disorders and malignant lymphomas
64. Molecular epidemiology of deletions and mutations of the latent membrane protein 1 oncogene of the Epstein-Barr virus in posttransplant lymphoproliferative disorders
65. BCL-2 but not its Epstein-Barr virus-encoded homologue, BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders
66. Receptors for B cell stimulatory factor 2: Quantitation, specificity, distribution, and regulation of their expression
67. Impairment of natural killer functions by interleukin-6 increases lymphoblastoid cell tumorigenicity in athymic mice